angiotensin-iii and Hypertension

The pathophysiology of heart failure (HF) and hypertension are thought to involve brain renin-angiotensin system (RAS) hyperactivity. Angiotensin III, a key effector peptide in the brain RAS, provides tonic stimulatory control over blood pressure (BP) in hypertensive rats. Aminopeptidase A (APA), the enzyme responsible for generating brain angiotensin III, constitutes a potential therapeutic target for hypertension treatment. We focus here on studies of RB150/firibastat, the first prodrug of the specific and selective APA inhibitor EC33 able to cross the blood-brain barrier. We consider its development from therapeutic target discovery to clinical trials of the prodrug. After oral administration, firibastat crosses the gastrointestinal and blood-brain barriers. On arrival in the brain, it is cleaved to generate EC33, which inhibits brain APA activity, lowering BP in various experimental models of hypertension. Firibastat was clinically and biologically well tolerated, even at high doses, in phase I trials conducted in healthy human subjects. It was then shown to decrease BP effectively in patients of various ethnic origins with hypertension in phase II trials. Brain RAS hyperactivity leads to excessive sympathetic activity, which can contribute to HF after myocardial infarction (MI). Chronic treatment with oral firibastat (4 or 8 weeks after MI) has been shown to normalize brain APA activity in mice. This effect is accompanied by a normalization of brain RAS and sympathetic activities, reducing cardiac fibrosis and hypertrophy and preventing cardiac dysfunction. Firibastat may therefore represent a novel therapeutic advance in the clinical management of patients with hypertension and potentially with HF after MI.

Topics: Angiotensin II; Angiotensin III; Animals; Antihypertensive Agents; Brain; Clinical Trials as Topic; Disulfides; Glutamyl Aminopeptidase; Heart Failure; Humans; Hypertension; Myocardial Infarction; Renin-Angiotensin System; Sulfonic Acids

The renin-angiotensin-aldosterone system (RAAS) plays a major role in the regulation of blood pressure and homeostasis. Therefore, it is a commonly used target for pharmacotherapy of cardiovascular diseases in adults. However, the efficacy of this pharmacotherapy can only be limitedly derived into children. Comprehensive knowledge of the humoral parameters acting in the paediatric RAAS (e.g. angiotensin I, angiotensin II, angiotensin 1-7, angiotensin III, and angiotensin IV) might facilitate a more effective and rational pharmacotherapy in children. Therefore, this review aims to provide an overview of the maturing RAAS. Out of 925 identified records, 35 publications were classified as relevant. Physiological and pathophysiological concentrations of angiotensin peptides were compiled and categorised according to European Medicines Agency age groups. Age has a major impact on circulating angiotensin I, angiotensin II, and angiotensin 1-7, which is reflected in an age-dependent decrease during childhood. In contrast to data obtained in adults, no gender-related differences in angiotensin levels were identified. The observed increase in peptide concentrations regarding cardiac- and renal-diseased children is influenced by surgical repair, while evidence for a pharmacological impact is conflicting. A comprehensive set of angiotensin I, angiotensin II, and angiotensin 1-7 values from neonates up to adolescents was compiled. Indicating age as a strong effector. However, evidence about potential promising targets of the RAAS like angiotensin III and angiotensin IV is still lacking in children.

Topics: Adolescent; Age Factors; Angiotensin I; Angiotensin II; Angiotensin III; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Child; Child, Preschool; Female; Humans; Hypertension; Infant; Infant, Newborn; Kidney Failure, Chronic; Male; Peptide Fragments; Renin-Angiotensin System

Renin angiotensin system (RAS) is an endogenous hormone system involved in the control of blood pressure and fluid volume. Dysregulation of RAS has a pathological role in causing cardiovascular diseases through hypertension. Among several key components of RAS, angiotensin peptides, varying in amino acid length and biological function, have important roles in preventing or promoting hypertension, cardiovascular diseases, stroke, vascular remodeling etc. These peptides are generated by the metabolism of inactive angiotensinogen or its derived peptides by hydrolyzing action of certain enzymes. Angiotensin II, angiotensin (1-12), angiotensin A and angiotensin III bind primarily to angiotensin II type 1 receptor and cause vasoconstriction, accumulation of inflammatory markers to sub-endothelial region of blood vessels and activate smooth muscle cell proliferation. Moreover, when bound to angiotensin II type 2 receptor, angiotensin II works as cardio-protective peptide and halt pathological cell signals. Other peptides like angiotensin (1-9), angiotensin (1-7), alamandine and angiotensin IV also help in protecting from cardiovascular diseases by binding to their respective receptors.

Topics: Angiotensin I; Angiotensin II; Angiotensin III; Angiotensinogen; Angiotensins; Animals; Blood Pressure; Humans; Hypertension; Oligopeptides; Peptide Fragments; Protective Factors; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Signal Transduction; Vasoconstriction

This review updates major new findings and concepts introduced during the past year on the role of angiotensin II (Ang II) subtype 2 receptors (AT2Rs) in the control of blood pressure and renal function.. AT2R activation prevents sodium (Na) retention and lowers blood pressure in the Ang II infusion model of experimental hypertension and prevents salt-sensitive hypertension in the obese Zucker rat model of obesity and the metabolic syndrome. Ang II metabolite, des-aspartyl-Ang II (Ang III) is the predominant AT2R agonist in the kidney and possibly also in the vasculature; a novel synthetic Ang III peptide, β-Pro-Ang III, is vasodepressor and lowers blood pressure in conscious spontaneously hypertensive rats in the presence of low-level Ang II type 1 receptor (AT1R) blockade. Because nitric oxide is a product of AT2R activation, a potential feed-forward loop, wherein nitric oxide increases AT2R transcription, may reinforce the beneficial actions of AT2R in the long term. AT2R activation also reduces proteinuria and oxidative stress in glomerulosclerotic kidneys of high-salt obese Zucker rats.. Studies during the past year have helped to clarify the physiological and pathophysiological roles of AT2Rs and have enhanced the promise of AT2R agonists in cardiovascular and renal disease.

Topics: Angiotensin II; Angiotensin III; Animals; Blood Pressure; Humans; Hypertension; Kidney; Nitric Oxide; Receptor, Angiotensin, Type 2; Sodium

Hypertension affects one-third of the adult population and is a growing problem due to the increasing incidence of obesity and diabetes. Brain RAS (renin-angiotensin system) hyperactivity has been implicated in the development and maintenance of hypertension in several types of experimental and genetic hypertension animal models. We have identified in the brain RAS that APA (aminopeptidase A) and APN (aminopeptidase N), two membrane-bound zinc metalloproteases, are involved in the metabolism of AngII (angiotensin II) and AngIII (angiotensin III) respectively. The present review summarizes the main findings suggesting that AngIII plays a predominant role in the brain RAS in the control of BP (blood pressure). We first explored the organization of the APA active site by site-directed mutagenesis and molecular modelling. The development and the use in vivo of specific and selective APA and APN inhibitors EC33 and PC18 respectively, has allowed the demonstration that brain AngIII generated by APA is one of the main effector peptides of the brain RAS, exerting a tonic stimulatory control over BP in conscious hypertensive rats. This identified brain APA as a potential therapeutic target for the treatment of hypertension, which has led to the development of potent orally active APA inhibitors, such as RB150. RB150 administered orally in hypertensive DOCA (deoxycorticosteroneacetate)-salt rats or SHRs (spontaneously hypertensive rats) crosses the intestinal, hepatic and blood-brain barriers, enters the brain, generates two active molecules of EC33 which inhibit brain APA activity, block the formation of brain AngIII and normalize BP for several hours. The decrease in BP involves two different mechanisms: a decrease in vasopressin release into the bloodstream, which in turn increases diuresis resulting in a blood volume reduction that participates in the decrease in BP and/or a decrease in sympathetic tone, decreasing vascular resistance. RB150 constitutes the prototype of a new class of centrally acting antihypertensive agents and is currently being evaluated in a Phase Ib clinical trial.

Topics: Angiotensin III; Animals; Binding Sites; Blood Pressure; Blood-Brain Barrier; Brain; Clinical Trials, Phase I as Topic; Disulfides; Drug Design; Glutamyl Aminopeptidase; Humans; Hypertension; Models, Molecular; Mutagenesis, Site-Directed; Protease Inhibitors; Rats; Sulfonic Acids

Hypertension affects 26% of adults and is in constant progress related to increased incidence of obesity and diabetes. One-third of hypertensive patients may be successfully treated with one antihypertensive agent, one-third may require two agents and in the remaining patients will need three agents for effective blood pressure (BP) control. The development of new classes of antihypertensive agents with different mechanisms of action therefore remains an important goal. Brain renin-angiotensin system (RAS) hyperactivity has been implicated in hypertension development and maintenance in several types of experimental and genetic hypertension animal models. Among the main bioactive peptides of the brain RAS, angiotensin (Ang) II and Ang III have similar affinities for type 1 (AT1) and type 2 (AT2) Ang II receptors. Following intracerebroventricular (i.c.v.) injection, Ang II and Ang III similarly increase arginine-vasopressin (AVP) release and BP. Blocking the brain RAS may be advantageous as it simultaneously (1) decreases sympathetic tone and consequently vascular resistance, (2) decreases AVP release, reducing blood volume and vascular resistance and (3) blocks angiotensin-induced baroreflex inhibition, decreasing both vascular resistance and cardiac output. However, as Ang II is converted to Ang III in vivo, the exact nature of the active peptide is not precisely determined. We summarize here the main findings identifying AngIII as one of the major effector peptides of the brain RAS in the control of AVP release and BP. Brain AngIII exerts a tonic stimulatory effect on BP in hypertensive rats, identifying brain aminopeptidase A (APA), the enzyme generating brain Ang III, as a potentially candidate target for hypertension treatment. This has led to the development of potent orally active APA inhibitors, such as RB150--the prototype of a new class of centrally acting antihypertensive agents.

Topics: Angiotensin III; Animals; Antihypertensive Agents; Brain; Drug Resistance; Glutamyl Aminopeptidase; Humans; Hypertension; Molecular Targeted Therapy; Nerve Tissue Proteins; Neurons; Protease Inhibitors; Renin-Angiotensin System

Aminopeptidase N (APN) or CD13 is a conserved type II integral membrane zinc-dependent metalloprotease in the M1 family of ectoenzymes. APN is abundant in the kidneys and central nervous system. Identified substrates include Angiotensin III (Ang III); neuropeptides, including enkephalins and endorphins; and homones, including kallidan and somatostatin. It is developmentally expressed, a myelomonocytic marker for leukemias, and a receptor for coronovirus. There is evolving support for APN in the regulation of arterial blood pressure and the pathogenesis of hypertension. In rodent strains, intracerebraventricular (i.c.v.) infusions of APN reduces, while inhibitors of APN activity have a pressor effect on blood pressure. Dysregulation of central APN has been linked to the pathogenesis of hypertension in the spontaneously hypertensive rat. There is evidence that renal tubule APN inhibits Na flux and plays a mechanistic role in salt-adaptation. A functional polymorphism of the ANP gene has been identified in the Dahl salt-sensitive rat. Signaling by APN impacting on blood pressure is likely mediated by regulation of the metabolism of Ang III to Ang IV. Whether APN regulates arterial blood pressure in humans or is a therapeutic target for hypertension are subjects for future exploration.

Topics: Angiotensin II; Angiotensin III; Animals; Blood Pressure; CD13 Antigens; Humans; Hypertension; Rats; Rats, Inbred Dahl; Rats, Inbred SHR

Among the main bioactive peptides of the brain renin-angiotensin system, angiotensin (Ang) II and AngIII exhibit the same affinity for the type 1 and type 2 Ang receptors. Both peptides, injected intracerebroventricularly, cause similar increase in blood pressure (BP). Because AngII is converted in vivo to AngIII, the identity of the true effector is unknown. This review summarized recent insights into the predominant role of brain AngIII in the central control of BP underlining the fact that brain aminopeptidase A (APA), the enzyme forming central AngIII, could constitute a putative central therapeutic target for the treatment of hypertension. This led to the development of potent, systematically active APA inhibitors, such as RB150, as a prototype of a new class of centrally acting antihypertensive agents for the treatment of certain forms of hypertension.

Topics: Angiotensin II; Angiotensin III; Animals; Antihypertensive Agents; Disulfides; Enzyme Inhibitors; Glutamyl Aminopeptidase; Hypertension; Models, Biological; Renin-Angiotensin System; Sulfonic Acids

The hyperactivity of the brain renin-angiotensin system (RAS) has been implicated in the development and maintenance of hypertension in several types of experimental and genetic hypertension animal models. Among the main bioactive peptides of the brain RAS, angiotensin (Ang) II and Ang III display the same affinity for type 1 and type 2 Ang II receptors. Both peptides, injected intracerebroventricularly, similarly increase blood pressure (BP); however, because Ang II is converted in vivo to Ang III, the identity of the true effector is unknown. In this article, we review new insights into the predominant role of brain Ang III in the control of BP, underlining the fact that brain aminopeptidase A (APA), the enzyme-forming central Ang III, could constitute a putative central therapeutic target for the treatment of hypertension. This justifies the development of potent systemically active APA inhibitors, such as RB150, as prototypes of a new class of antihypertensive agents for the treatment of certain forms of hypertension.

Topics: Angiotensin III; Animals; Antihypertensive Agents; Blood Pressure; Brain; Glutamyl Aminopeptidase; Humans; Hypertension

Topics: Angiotensin I; Angiotensin II; Angiotensin III; Biomarkers; Chromatography, High Pressure Liquid; Cushing Syndrome; Diagnosis, Differential; Diagnostic Techniques, Endocrine; Humans; Hyperaldosteronism; Hypertension; Hypertension, Renovascular; Myocardial Infarction; Radioimmunoassay; Reference Values; Renin-Angiotensin System; Specimen Handling; Water-Electrolyte Imbalance

Overactivity of the brain renin-angiotensin system (RAS) has been implicated in the development and maintenance of hypertension in several experimental animal models. We have recently reported that, in the murine brain RAS, angiotensin II (AngII) is converted by aminopeptidase A (APA) into angiotensin III (AngIII),which is itself degraded by aminopeptidase N (APN), both peptides being equipotent to increase vasopressin release and arterial blood pressure when injected by the intracerebroventricular (i.c.v.) route. Because AngII is converted in vivo into AngIII, the exact nature of the active peptide is not precisely known. To delineate their respective roles in the central control of cardiovascular functions, specific and selective APA and APN inhibitors are needed to block the metabolic pathways of AngII and AngIII respectively. In the absence of such compounds for APA, we first explored the organization of the APA active site by site-directed mutagenesis. This led us to propose a molecular mechanism of action for APA similar to that proposed for the bacterial enzyme thermolysin deduced from X-ray diffraction studies. Secondly, we developed a specific and selective APA inhibitor, compound EC33 [(S)-3-amino-4-mercaptobutylsulphonic acid], as well as a potent and selective APN inhibitor, PC18 (2-amino-4-methylsulphonylbutane thiol). With these new tools we examined the respective roles of AngII and AngIII in the central control of arterial blood pressure. A central blockade of APA with the APA inhibitor EC33 suppressed the pressor effect of exogenous AngII, suggesting that brain AngII must be converted into AngIII to increase arterial blood pressure. Furthermore, EC33, injected alone i.c.v. but not intravenously, caused a dose-dependent decrease in arterial blood pressure by blocking the formation of brain AngIII but not systemic AngIII. This is corroborated by the fact that the selective APN inhibitor PC18 administered alone via the i.c.v. route increased arterial blood pressure. This pressor response was blocked by prior treatment with the angiotensin type 1 receptor antagonist losartan, showing that blocking the action of APN on AngIII metabolism leads to an increase in endogenous AngIII levels, resulting in arterial blood pressure increase through an interaction with angiotensin type 1 receptors. These results demonstrate that AngIII is a major effector peptide of the brain RAS, exerting a tonic stimulatory control over arterial blood pressure. Thus AP

Topics: Aminopeptidases; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arteries; Binding Sites; Blood Pressure; Brain; CD13 Antigens; Dose-Response Relationship, Drug; Glutamyl Aminopeptidase; Hypertension; Hypothalamus; Losartan; Mice; Models, Chemical; Mutagenesis, Site-Directed; Peptides; Rats; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Thermolysin; Vasopressins

Angiotensin II is recognised as the principle active peptide of the renin-angiotensin system, exerting effects on fluid and electrolyte homeostasis, and cardiovascular control including neural and long term trophic effects. However, recent studies indicate that other angiotensin peptides such as angiotensin III, angiotensin II (1-7) and angiotensin IV, may have specific actions. Interestingly, recent work involving angiotensin IV demonstrates that this peptide binds to specific receptors and may be involved in memory retention and neuronal development. Furthermore, our demonstration that a globin fragment, LVV-haemorphin-7, binds with high affinity to the angiotensin IV binding site and is abundant in the brain, indicates that this may represent a novel brain neuropeptide system. It now appears, that the renin-angiotensin system is more complex than previously thought and capable of generating multiple, active peptides which elicit numerous diverse actions.

Topics: Angiotensin II; Angiotensin III; Animals; Blood Pressure; Humans; Hypertension; Peptide Fragments; Peptides; Renin-Angiotensin System; Sensitivity and Specificity

Renin plays a major role in the control of blood pressure and water and electrolyte metabolism and it is clear that blocking of this system is particularly effective in the treatment of essential hypertension and heart failure. A large number of converting enzyme inhibitors have been synthesized. Converting enzyme inhibitors are remarkably active in heart failure and they reduce microalbuminuria and possibly maintain glomerular function. Blocking of the renin-angiotensin system by converting enzyme inhibitors is not accompanied by hypotension or reflex stimulation of the sympathetic nervous system. Converting enzyme inhibitors represent a major therapeutic advance in the field of cardiovascular and renal disease but the long-term effects of decreased angiotensin II levels are unknown. There are other ways to inhibit the renin-angiotensin system. The recent discovery of orally-active non-peptide angiotensin II antagonists opens a range of fascinating prospects. Another approach consists in inhibiting the reaction of renin on angiotensinogen, which is remarkably selective. Although it is too early to know whether these new approaches will be less active, more active or as active as current converting enzyme inhibitors, they may constitute a progress in relation to currently available treatments.

Topics: Angiotensin II; Angiotensin III; Angiotensin-Converting Enzyme Inhibitors; Animals; Heart Failure; Humans; Hypertension; Renin-Angiotensin System

Topics: Angiotensin I; Angiotensin II; Angiotensin III; Animals; Extraembryonic Membranes; Female; Genitalia, Female; Humans; Hypertension; Menstrual Cycle; Ovary; Postpartum Period; Pregnancy; Pregnancy Complications, Cardiovascular; Prostaglandins; Rabbits; Renin; Reproduction; Research

Topics: Adrenal Cortex Function Tests; Adrenal Cortex Neoplasms; Adrenocorticotropic Hormone; Aldosterone; Angiotensin III; Cushing Syndrome; Diagnosis, Differential; Humans; Hyperaldosteronism; Hypertension; Mixed Function Oxygenases; Pheochromocytoma; Pituitary-Adrenal Function Tests; Renin

Topics: Angiotensin I; Angiotensin II; Angiotensin III; Angiotensinogen; Animals; Humans; Hypertension; Kidney; Oligopeptides; Pepstatins; Renin; Renin-Angiotensin System; Teprotide

The renin-angiotensin system has an important role in maintaining elevated blood pressure levels in certain forms of experimental and human hypertension. Renin, an enzyme produced by the juxtaglomerular cells of the kidney, acts on a protein substrate found in the alpha 2-globulin fraction of the plasma to produce a decapeptide, angiotensin I. This decapeptide is not directly pressor, but on passage through the pulmonary circulation is converted to an octapeptide, angiotensin II, a very potent pressor substance which acts by causing constriction of arteriolar smooth muscle. In addition to its direct action which increases blood pressure, angiotensin II acts on the adrenal cortex to cause the release of the sodium-retaining hormone aldosterone. Recent evidence suggests that this action may be mediated by the heptapeptide, angiotensin III. Both renin and its protein substrate exist in multiple forms and renin may also exist as a high molecular-weight "pro-hormone," although the physiologic significance of these forms is not clear. The elucidation of the biochemistry of the renin-angiotensin system has provided us with inhibitors which allow the system to be blocked effectively in vivo. Thus, angiotensin antagonists such as Sar 1, IIe 8-angiotensin II and converting enzyme inhibitors such as BPP 9a (SQ 20881) have proved useful in the study of experimental and human hypertension.

Topics: Aldosterone; Angiotensin II; Angiotensin III; Angiotensinogen; Animals; Cattle; Dogs; Endopeptidases; Humans; Hypertension; Peptidyl-Dipeptidase A; Rabbits; Rats; Renin; Swine

In the brain, aminopeptidase A (APA), a membrane-bound zinc metalloprotease, generates angiotensin III from angiotensin II. Brain angiotensin III exerts a tonic stimulatory effect on the control of blood pressure (BP) in hypertensive rats and increases vasopressin release. Blocking brain angiotensin III formation by the APA inhibitor prodrug RB150/firibastat normalizes arterial BP in hypertensive deoxycorticosterone acetate (DOCA)-salt rats without inducing angiotensin II accumulation. We therefore hypothesized that another metabolic pathway of brain angiotensin II, such as the conversion of angiotensin II into angiotensin 1-7 (Ang 1-7) by angiotensin-converting enzyme 2 (ACE2) might be activated following brain APA inhibition. We found that the intracerebroventricular (icv) administration of RB150/firibastat in conscious DOCA-salt rats both inhibited brain APA activity and induced an increase in brain ACE2 activity. Then, we showed that the decreases in BP and vasopressin release resulting from brain APA inhibition with RB150/firibastat were reduced if ACE2 was concomitantly inhibited by MLN4760, a potent ACE2 inhibitor, or if the Mas receptor (MasR) was blocked by A779, a MasR antagonist. Our findings suggest that in the brain, the increase in ACE2 activity resulting from APA inhibition by RB150/firibastat treatment, subsequently increasing Ang 1-7 and activating the MasR while blocking angiotensin III formation, contributes to the antihypertensive effect and the decrease in vasopressin release induced by RB150/firibastat. RB150/firibastat treatment constitutes an interesting therapeutic approach to improve BP control in hypertensive patients by inducing in the brain renin-angiotensin system, hyperactivity of the beneficial ACE2/Ang 1-7/MasR axis while decreasing that of the deleterious APA/Ang II/Ang III/ATI receptor axis.

Topics: Angiotensin III; Angiotensin-Converting Enzyme 2; Animals; Antihypertensive Agents; Brain; Desoxycorticosterone Acetate; Disease Models, Animal; Disulfides; Glutamyl Aminopeptidase; Hypertension; Male; Mice; Rats, Wistar; Sodium Chloride, Dietary; Sulfonic Acids

See Article Kemp et al.

Topics: Angiotensin II; Angiotensin III; Animals; Antihypertensive Agents; Hypertension; Kidney; Kidney Tubules, Proximal; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Signal Transduction; Sodium-Hydrogen Exchanger 3; Sodium-Hydrogen Exchangers

We have previously shown that individual β-amino acid substitution in angiotensin (Ang) II reduced Ang II type 1 receptor (AT1R) but not Ang II type 2 receptor (AT2R)-binding and that the heptapeptide Ang III exhibited greater AT2R:AT1R selectivity than Ang II. Therefore, we hypothesized that β-amino-acid-substituted Ang III peptide analogues would yield highly selective AT2R ligands, which we have tested in binding and functional vascular assays. In competition binding experiments using either AT1R- or AT2R-transfected human embryonic kidney (HEK)-293 cells, novel β-substituted Ang III analogues lacked appreciable AT1R affinity, whereas most compounds could fully displace (125)I-Sar(1)Ile(8) Ang II from AT2R. The rank order of affinity at AT2R was CGP42112 > Ang III > β-Pro(7) Ang III=Ang II > β-Tyr(4) Ang III ≥ PD123319 >> β-Phe(8) Ang III >> β Arg(2) Ang III=β-Val(3) Ang III >> β-Ile(5) Ang III. The novel analogue β-Pro(7) Ang III was the most selective AT2R ligand tested, which was >20,000-fold more selective for AT2R than AT1R. IC50 values at AT2R from binding studies correlated with maximum vasorelaxation in mouse aortic rings. Given that β-Pro(7) Ang III was an AT2R agonist, we compared β-Pro(7) Ang III and native Ang III for their ability to reduce blood pressure in separate groups of conscious spontaneously hypertensive rats. Whereas Ang III alone increased mean arterial pressure (MAP), β-Pro(7) Ang III had no effect. During low-level AT1R blockade, both Ang III and β-Pro(7) Ang III, but not Ang II, lowered MAP (by ∼30 mmHg) at equimolar infusions (150 pmol/kg/min for 4 h) and these depressor effects were abolished by the co-administration of the AT2R antagonist PD123319. Thus, β-Pro(7) Ang III has remarkable AT2R selectivity determined in binding and functional studies and will be a valuable research tool for insight into AT2R function and for future drug development.

Topics: Amino Acid Sequence; Analysis of Variance; Angiotensin II Type 2 Receptor Blockers; Angiotensin III; Animals; Aorta, Thoracic; Benzimidazoles; Binding, Competitive; Biphenyl Compounds; Drug Stability; HEK293 Cells; Humans; Hypertension; Imidazoles; In Vitro Techniques; Inhibitory Concentration 50; Isometric Contraction; Male; Mice; Muscle, Smooth, Vascular; Pyridines; Rats; Receptors, Angiotensin; Tetrazoles; Vasoconstrictor Agents; Vasodilation

In Sprague-Dawley rats, renal angiotensin (Ang) type 2 receptors (AT(2)Rs) mediate natriuresis in response to renal interstitial (RI) D(1)-like receptor stimulation or RI Ang III infusion. After D(1)-like receptor activation, apical membrane (AM) but not total renal proximal tubule cell AT(2)R expression is increased, suggesting that AM AT(2)R translocation may be important for natriuresis. The onset of hypertension in spontaneously hypertensive rats (SHRs) is preceded by defects in renal sodium excretion. The present study examines AT(2)R-mediated natriuresis in response to RI Ang III infusion in Wistar-Kyoto rats (WKYs) and SHRs. WKYs and SHRs received RI Ang III infusion after 24 hours of systemic AT(1)R blockade with candesartan. In WKYs, urine sodium excretion rate increased from 0.043+/-0.01 to 0.191+/-0.06 micromol/min (P<0.05) in response to Ang III infusion, but identical conditions failed to increase the urine sodium excretion rate in SHRs. The increase in the urine sodium excretion rate was blocked by coinfusion of PD-123319, a selective AT(2)R antagonist. On confocal microscopy images, Ang III-infused WKYs demonstrated greater renal proximal tubule cell AM AT(2)R fluorescence intensity compared with SHRs (5385+/-725 versus 919+/-35; P<0.0001), and Western blot analysis demonstrated increased AM (0.050+/-0.003 versus 0.038+/-0.003; P<0.01) but not total cell AT(2)R expression in WKYs. In SHRs, AM AT(2)R expression remained unchanged in response to RI Ang III infusion. Thus, RI Ang III infusion elicits natriuresis and renal proximal tubule cell AT(2)R translocation in WKYs. Identical manipulations fail to induce natriuresis or AT(2)R translocation in SHRs, suggesting that defects in AT(2)R-mediated natriuresis and trafficking may be important to the development of hypertension in SHRs.

Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin III; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cell Membrane; Disease Models, Animal; Female; Hypertension; Imidazoles; Kidney Tubules, Proximal; Natriuresis; Pyridines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Sodium; Tetrazoles

Angiotensin II upregulates the expression of LOX-1, a recently identified oxidized low-density lipoprotein receptor controlled by redox state which in turn upregulates angiotensin II activity on its activation. To test whether interruption of this positive feedback loop might reduce angiotensin II-induced hypertension and subsequent renal injury, we studied LOX-1 knockout mice. After infusion with angiotensin II for 4 weeks systolic blood pressure gradually increased in the wild-type mice; this rise was significantly attenuated in the LOX-1 knockout mice. Along with the rise in systolic blood pressure, renal function (blood urea nitrogen and creatinine) decreased in the wild-type mice, but the deterioration of function was significantly less in the LOX-1 knockout mice. Glomerulosclerosis, arteriolar sclerosis, tubulointerstitial damage, and renal collagen accumulation were all significantly less in the LOX-1 knockout mice. The reduction in collagen formation was accompanied by a decrease in connective tissue growth factor mRNA, angiotensin type 1 receptor expression, and phosphorylation of p38 and p44/42 mitogen-activated protein kinases. Expression of endothelial nitric oxide synthase was increased in the kidneys of the LOX-1 knockout mice compared to the wild-type mice. Overall, our study suggests that LOX-1 is a key modulator in the development of angiotensin II-induced hypertension and subsequent renal damage.

Topics: Angiotensin III; Animals; Blood Pressure; Connective Tissue Growth Factor; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Hypertension; Kidney; Male; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type III; p38 Mitogen-Activated Protein Kinases; Receptor, Angiotensin, Type 1; Scavenger Receptors, Class E

Topics: Angiotensin II; Angiotensin III; Animals; Blood Pressure; Blood-Brain Barrier; Disease Models, Animal; Enzyme Inhibitors; Glutamyl Aminopeptidase; Humans; Hypertension; Rats; Renin-Angiotensin System; Sulfonic Acids

The in vitro anti-hypertrophic and hyperplastic actions of des-aspartate-angiotensin I (DAA-I) on cultured cardiovascular cells have been demonstrated in earlier experiments. The present study investigated its effects on the development of neointima in balloon catheter-injured carotid artery of the Sprague-Dawley (SD) rat and the development of cardiovascular hypertrophy in the spontaneously hypertensive rat. Treatment with i.v. DAA-I for 14 days post-injury dose-dependently attenuated the development of neointima. The maximum effect was obtained at 34 pmol/kg/day. The data support the possibility that endogenous angiotensins could inhibit neointima growth. This opens up avenues for their therapeutic elevation in combating neointima-related restenosis of which current drugs are not fully effective in suppressing. Five-week-old pre-hypertensive SHR, when orally administered with a dose of 769 nmol/kg/day DAA-I for a duration of 47 weeks, showed significant reduction in the development of cardiac and vascular hypertrophy compared to the untreated controls. Similar treatment with DAA-I had no effect on the Wistar Kyoto rats. The present findings support the contention that, besides angiotensin II, other endogenous angiotensins are also involved in the regulation and/or pathophysiology of the cardiovascular system.

Topics: Angiotensin I; Angiotensin III; Animals; Arterial Occlusive Diseases; Arteriosclerosis; Cardiomegaly; Cardiomyopathy, Hypertrophic; Dose-Response Relationship, Drug; Hypertension; Injections, Intravenous; Male; Rats; Tunica Intima

An earlier study showed that des-aspartate-angiotensin I (DAA-I) attenuated the pressor action of angiotensin III in aortic rings of the spontaneously hypertensive rat (SHR) but not the normotensive Wistar Kyoto (WKY) rat. The present study investigated similar properties of DAA-I in isolated perfused kidneys and mesenteric beds of WKY and SHR. In the renal vasculature, angiotensin III induced a dose-dependent pressor response, which was more marked in the SHR than WKY in terms of significant greater magnitude of response and lower threshold. DAA-I attenuated the pressor action of angiotensin III in both the WKY and SHR. The attenuation in SHR was much more marked, occurring at doses as low as 10(-15) M DAA-I, while effective attenuation was only seen with 10(-9) M in WKY. The effects of DAA-I was not inhibited by PD123319 and indomethacin, indicating that its action was not mediated by angiotensin AT2 receptors and prostaglandins. However, the direct pressor action of angiotensin III in the SHR but not the WKY was attenuated by indomethacin suggesting that this notable difference could be due to known decreased response of renal vasculature to vasodilator prostaglandins in the SHR. Pressor responses to angiotensin III in the mesenteric vascular bed was also dose dependent, but smaller in magnitude compared to the renal response. The responses in the SHR, though generally smaller, were not significantly different from those of the WKY. This trend is in line with the similar observations with angiotensin III and II by other investigators. In terms of the effect of DAA-I, indomethacin and PD123319 on angiotensin III action, similar patterns to those of the renal vasculature were observed. This reaffirms that in the perfused kidney and mesenteric bed, where the majority of the vessels are contractile, femtomolar concentrations of DAA-I attenuates the pressor action of angiotensin III. The attenuation is not indomethacin sensitive and does not involve the angiotensin AT2 receptor. The findings suggest that DAA-I possesses protective vascular actions and is involved in the pathophysiology of hypertension.

Topics: Angiotensin I; Angiotensin II Type 2 Receptor Blockers; Angiotensin III; Animals; Blood Pressure; Blood Vessels; Cardiovascular Agents; Hypertension; Imidazoles; Indomethacin; Kidney; Male; Mesenteric Artery, Superior; Prostaglandins; Pyridines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Angiotensin, Type 2; Vasoconstrictor Agents

Angiotensin (Ang) II is the active component of the renin-angiotensin-system (RAS), but its degradation products have also been shown to exhibit biological activity. This system, which mainly controls blood pressure and electrolyte homeostasis, was recently found to be completely expressed in human adipose tissue. The major determinant in the fibrinolytic system is the plasminogen activator inhibitor-1 (PAI-1). Both PAI-1 and components of the RAS are over-expressed in the obese state. We have recently shown that Ang II is able to induce PAI-1 expression and release via the AT1-receptor in human fat cells in primary culture, and have provided the first evidence that two metabolites, Ang III and Ang IV, may have a similar stimulatory effect on PAI-1 release. We have now performed additional experiments to further characterize the role of the angiotensin peptides in the production of PAI-1. Ang III and Ang IV showed a time- and dose-dependent stimulation of PAI-1 protein release. Concomitantly, mRNA-levels were markedly elevated. Using specific receptor blockers, all angiotensin peptides seem to induce PAI-1 expression via the angiotensin receptor subtype 1. However, components of the renin-angiotensin-system seem to play an important role in the control of fibrinolysis in adipose tissue. We conclude that PAI-1 production by adipose tissue may contribute to the elevated thromboembolic risk in obesity.

Topics: Adipocytes; Adult; Angiotensin II; Angiotensin III; Cells, Cultured; Female; Fibrinolysis; Gene Expression; Humans; Hypertension; Middle Aged; Obesity; Plasminogen Activator Inhibitor 1; Renin-Angiotensin System

The actions of des-Asp angiotensin I, a nine aminoacid peptide, on the contractility of the aortic rings of the normotensive Wistar Kyoto rats (WKY) and spontaneously hypertensive rats (SHR) were studied. In the presence of captopril which prevented its degradation to angiotensin III by angiotensin converting enzyme, des-Asp-angiotensin I exerted direct concentration-dependent contractile action on the aortic rings. The contractile action was concentration-dependently attenuated by the AT1 receptor antagonist, losartan, but was not affected by the AT2 receptor antagonist, PD123319; indicating that angiotensin AT1 receptors mediate the direct contractile action. The response to des-Asp-angiotensin I was qualitatively different from that to angiotensin III i.e. lower potency and a likely higher efficacy suggesting that the two angiotensins act on different subtypes of angiotensin receptor. The response of the aortic rings to angiotensin III and des-Asp-angiotensin I in the SHR was significantly lower than the corresponding responses in WKY. Des-Asp-angiotensin I attenuated in a concentration-dependent and U-shape manner the response of the aortic ring to angiotensin III in the SHR but not in the WKY. Significant attenuation occurred in the pico to nano molar range of des-Asp-angiotensin I which is within the physiological concentration of the nonapeptide. Although these findings are the first demonstration of a direct and modulatory action of des-Asp-angiotensin I on the blood vessels of the SHR and raise the possibility of its involvement in blood pressure control, its exact role remains to be further studied.

Topics: Angiotensin I; Angiotensin II; Angiotensin III; Animals; Aorta; Drug Evaluation, Preclinical; Hypertension; In Vitro Techniques; Logistic Models; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Vasoconstriction

When angiotensin fragments, Val-Tyr and Angiotensin III (ANG III), with potent ACE inhibitory activity were intravenously administered to spontaneously hypertensive rat (SHR), a significant reduction of diastolic blood pressure was observed. After incubation of ANG III with SHR plasma, four fragments with ACE inhibitory activity, Val-Tyr (ANG (3-4)) (IC50 = 26.0 microM), Ile-His-Pro-Phe (ANG (5-8)) (11.6 microM), Tyr-Ile-His-Pro-Phe (ANG (4-8)) (457.5 microM), and Val-Tyr-Ile-His-Pro-Phe (ANG (3-8)) (6.55 microM), were confirmed to generate in SHR plasma. Compared the metabolic behavior of ANG II in SHR plasma with that in normotensive Wistar plasma, the initial degradation rate (3.07 nmol/ml/min) in Wistar plasma was about 2-fold higher than that in the SHR one (1.75 nmol/ml/min).

Topics: Amino Acid Sequence; Angiotensin II; Angiotensin III; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Hypertension; Male; Molecular Sequence Data; Peptide Fragments; Peptidyl-Dipeptidase A; Rats; Rats, Inbred SHR; Structure-Activity Relationship

The conscious spontaneously hypertensive rat (SHR), compared to its normotensive control Wistar Kyoto rat (WKY), exhibited a significantly greater pressor response to i.v. angiotensin II and angiotensin III. Losartan (10 mg/kg i.v.) lowered the basal blood pressure of the SHR but had no significant effect on that of the WKY. However, it attenuated the pressor response to both angiotensins in the SHR and WKY, the degree of attenuation being significantly greater with angiotensin III. In addition, the pressor responses induced by both angiotensin II and angiotensin III in the WKY, compared to those of the SHR, were more markedly inhibited by losartan. The results indicate a possible over-expression of angiotensin AT1 receptors in the SHR, and that both angiotensin II and angiotensin III contribute to the hypertension by acting on these receptors.

Topics: Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Hypertension; Imidazoles; Losartan; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles

In dispersed rabbit adrenocortical glomerulosa cells, a non-peptide angiotensin II (AT1) receptor antagonist, CV-11974 (10(-10)-10(-5) M), competitively inhibited angiotensin II- or angiotensin III-stimulated aldosterone production, whereas PD123177, an angiotensin AT2 receptor antagonist, did not. CV-11974 inhibited aldosterone production induced by 4 mM K+ but not by 12 mM K+. CV-11974 had no effect on adrenocorticotropic hormone-stimulated aldosterone or corticosterone production, but inhibited angiotensin II-stimulated corticosterone production. In the rat, TCV-116, the prodrug of CV-11974, (0.1 and 1 mg/kg, p.o.) markedly reduced the elevation of both plasma aldosterone concentration and blood pressure induced by i.v. infusion of angiotensin II. In spontaneously hypertensive rats, TCV-116 at daily p.o. doses of 0.1, 1 and 10 mg/kg for 2 weeks caused a dose-dependent reduction of blood pressure and plasma aldosterone concentration without affecting plasma corticosterone. Thus, TCV-116 inhibited the induction of aldosterone production by not only exogenous but also endogenous angiotensin II.

Topics: Administration, Oral; Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Cells, Cultured; Corticosterone; Hypertension; Imidazoles; Infusions, Intravenous; Male; Pyridines; Rabbits; Rats; Rats, Inbred SHR; Rats, Wistar; Tetrazoles; Zona Glomerulosa

The cardiovascular role of angiotensin III (ANG III) in the central nervous system is unclear. In this study, we investigated the hemodynamic effects of microinjection of ANG III and compared them with those of angiotensin II (ANG II) into the cerebral ventricle (i.c.v.), the area postrema (AP) and the nucleus tractus solitarii (NTS) of urethane-anesthetized rats. Male Sprague-Dawley rats [normal, renovascular hypertensive (2-kidney, 1-clip) and sham-operated groups] were used in this study. A dose-dependent pressor and bradycardic effect of ANG II and ANG III was observed after i.c.v. injection. When low doses of ANG II or ANG III were microinjected into both NTS and AP, a dose-dependent depressor and bradycardic effect were observed. The maximal depressor effect was observed at 9.6 pmol. When we increased the doses of ANG II or ANG III into the NTS, a pressor and tachycardic effect were observed. A significant difference of the cardiovascular effects of ANG III were noticed between renovascular hypertensive rats and sham-operated rats. The sympathetic nerve activity was inhibited by both pressor and depressor effects. The cardiovascular actions of both ANG II and ANG III were partially or completely abolished after pretreatment of their selective antagonists. These results indicate that the pressor effect of i.c.v. angiotensin are not mediated by activations of angiotensin receptors in the NTS or in the AP.

Topics: Angiotensin II; Angiotensin III; Animals; Blood Pressure; Brain Stem; Heart Rate; Hypertension; Male; Rats; Rats, Sprague-Dawley; Sympathetic Nervous System

We evaluated the chronic effect of angiotensin-III (AIII) in the promotion of drinking behavior in spontaneously hypertensive (SH) and normotensive Wistar-Kyoto (WKY) rats, using conscious, freely moving, male, adult animals that had been instrumented with an intracerebroventricular (icv) cannula connected to an osmotic mini-pump for 7-day infusion. Chronic icv infusion of AIII (5 or 10 pmol/min) elicited robust, dose-dependent, and Ile7-AIII (100 pmol/min; as specific antagonist)-reversible dipsogenesis in both SH and WKY rats, with higher water intake in the former strain. However, the drinking response in the SHRs exhibited a sharp drop after 3 days of AIII infusion, during which acute AIII (80 pmol, icv) challenges also failed to induce dipsogenesis. Chronic icv infusion of bestatin (150 pmol/min), an aminopeptidase-B inhibitor, did not by itself discernibly affect basal drinking. When combined with AIII (5 or 10 pmol/min), however, bestatin, respectively, suppressed and augmented the dipsogenic response of SH and WKY rats to the heptapeptide. These results suggest that chronic administration of AIII did not produce sustained drinking behavior in SHRs, possibly because of the development of early desensitization of the angiotensin receptors.

Topics: Aminopeptidases; Angiotensin III; Animals; Carbachol; Cerebral Ventricles; Drinking; Hypertension; Leucine; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY

The acute effects of intracerebroventricular (i.c.v.) administration of angiotensin III (ANG III) on blood pressure (BP) and renal function were investigated in spontaneously hypertensive rats (SHR, n = 31) and Wistar-Kyoto (WKY) normotensive rats (n = 6). ANG II was also administered to the same rats for comparison of its renal effect. BP and renal clearance responses were measured before and during ANG injections. The results showed that i.c.v. injections of 1, 5 and 50 pmol of ANG III did not significantly alter BP in SHR, but a high dose of ANG III (50 pmol) caused a vasopressor effect (7 +/- 4 mmHg) in WKY rats. There were significant increases in renal plasma flow (RPF), glomerular filtration rate (GFR), urine flow, absolute and fractional excretions of sodium and potassium, osmolar clearance and free water reabsorption rate following i.c.v. administration of ANG III in both SHR and WKY rats. However, the enhancement in renal responsiveness to ANG III was greater in SHR than in the WKY group. At 5 pmol of ANG III, the peak increases in GFR (96 +/- 23%), diuresis (316 +/- 102%) and natriuresis (712 +/- 281%) in SHR were significantly greater than those in WKY rats (40 +/- 13%, 152 +/- 89%, 229 +/- 130%, resp.). The renal effect of central ANG III was blocked by i.c.v. ANG III antagonist, [Ile7]-ANG III, but was enhanced by bestatin, an ANG III metabolic enzyme inhibitor. I.c.v. administration of ANG II at 50 pmol increased BP in both SHR and WKY rats (14 +/- 3 and 10 +/- 3 mmHg, resp.). Greater diuretic and natriuretic responses to ANG II were also noted in SHR than in WKY rats. These results indicate that central ANG III is as active as ANG II in modulating renal function. Furthermore, the enhanced renal response to i.c.v. ANGs II and III in SHR suggests a hyperactive central RAS implicated in BP and body fluid regulation in this genetic hypertensive strain.

Topics: Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Hypertension; Injections, Intraventricular; Kidney; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY

1. The responses of angiotensin II (AII), AIII, aldosterone and plasma renin activity (PRA) to a single dose of captopril were investigated in hypertensive patients receiving long-term (more than 1 year) captopril therapy (CT patients) and compared with those of non-treated hypertensive patients (NT patients). 2. Baseline levels of AII and aldosterone were significantly lower in CT patients than in NT patients. AIII tended to be lower and PRA was slightly higher in CT than in NT patients, but these differences were not significant. 3. A single administration of captopril (50 mg orally) significantly decreased plasma levels of AII, AIII and aldosterone as well as blood pressure in both CT and NT patients. 4. These results demonstrate that chronically repeated administration of captopril to hypertensive patients effectively reduces the daily blood pressure and concomitantly the plasma AII level to acceptable levels in patients with no experience of ACE inhibition.

Topics: Aldosterone; Angiotensin II; Angiotensin III; Blood Pressure; Captopril; Drug Tolerance; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Renin; Renin-Angiotensin System

Topics: Aldosterone; Angiotensin III; Circadian Rhythm; Humans; Hyperaldosteronism; Hypertension; Reference Values; Renin

In vitro results indicated that human placenta-derived aminopeptidase A (APA) was very effective at hydrolyzing aspartate from the angiotensin molecule, thus converting angiotensin II to angiotensin III, but was not active against angiotensin III. In vivo experiments revealed significant elevations in blood pressure when APA was intracerebroventricularly infused into anesthetized spontaneously hypertensive rats (SHR) and Wistar-Kyoto normotensive control rats (WKY), with maximum mean (+/- s.e.m.) increases of 30.0 +/- 2.5 and 32.5 +/- 3.7 mmHg, respectively. By contrast, in vitro incubation results utilizing leucine aminopeptidase M (LAP-M) indicated very active degradation of angiotensin III, with less rapid degradation of angiotensin II. The intracerebroventricular infusion of LAP-M significantly reduced blood pressure, particularly in the SHR, but also in WKY, -65.8 +/- 5.1 and -42.5 +/- 6.1 mmHg, respectively. Pretreatment with the specific angiotensin receptor antagonist, Sar1, Thr8 angiotensin II (sarthran) significantly diminished the subsequent APA-induced increase in blood pressure in members of both strains. Pretreatment with sarthran has previously been shown to significantly diminish LAP-M-induced decreases in blood pressure in SHR. Thus, the effects of these aminopeptidases appear to be primarily dependent upon the brain angiotensinergic system, and are consistent with the hypothesis that angiotensin III is the primary active form of central angiotensin.

Topics: Aminopeptidases; Angiotensin II; Angiotensin III; Animals; Blood Pressure; Brain; Glutamyl Aminopeptidase; Humans; Hypertension; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY

The degradation pattern and rate of [Ile5]-Angiotensin (Ang) I, II, and III were studied in neuron-enriched and glia-enriched cells in primary cultures from rat brain. Metabolites were separated by HPLC, and their identities were evaluated by comparison of their retention times with those of synthetic Ang peptide fragments and by analysis of their amino acid composition. Major metabolites were identified as des-Asp1-[Ile5]-Ang I, des-Asp1-[Ile5]-Ang II, [Ile5]-Ang II (3-8) hexapeptide, [Ile5]-Ang II (4-8) pentapeptide, and [Ile5]-Ang II (5-8) tetrapeptide. Glia-enriched cells degraded [Ile5]-Ang I and [Ile5]-Ang III significantly faster than neuron-enriched cells, whereas no difference between the two types of cells was found in the degradation rate of [Ile5]-Ang II. Although the half-lives of [Ile5]-Ang I and [Ile5]-Ang III in neuron-enriched cells from normotensive Wistar-Kyoto (WKY) rats and spontaneously hypertensive rats (SHR) were not significantly different, neuron-enriched cultures from WKY rats metabolized [Ile5]-Ang II about 2.6 times faster than neuron-enriched cells derived from SHR.

Topics: Angiotensin I; Angiotensin II; Angiotensin III; Angiotensins; Animals; Cells, Cultured; Chromatography, High Pressure Liquid; Hypertension; Kinetics; Neuroglia; Neurons; Peptide Fragments; Peptidyl-Dipeptidase A; Rats; Rats, Inbred SHR; Rats, Inbred WKY

In the present study, effects of angiotensin on the adrenal steroidogenesis were studied in essential hypertension, primary aldosteronism and renovascular hypertension (RVH). Angiotensin III(A III), an analogue of angiotensin II, was administered to 17 normal volunteers (9 male and 8 female), 44 patients with essential hypertension (EH) (15 with high renin; HREH, 15 with normal renin; NREH and 14 with low renin; LREH), 8 patients with primary aldosteronism (5 with adrenal adenoma; APA and 3 with bilateral adrenocortical hyperplasia; IHA) and 5 patients with renovascular hypertension. In all the patients with hypertension and normal subjects, blood pressure (BP) and plasma concentrations of progesterone (P), corticosterone (B), aldosterone (Aldo), 17 alpha-hydroxyprogesterone(17-OHP) and cortisol(F) were measured before and after intravenous administration of A III (0.1, 0.5, 1.0, 10, 20 and 40 ng/kg/min, for 15 min, respectively). 1) BP rose from 164 +/- 19/88 +/- 8 to 180 +/- 19/112 +/- 10 mmHg [systolic BP(SBP); P less than 0.01, diastolic BP(DBP); P less than 0.01] in HREH, from 162 +/- 12/96 +/- 7 to 186 +/- 11/118 +/- 8 mmHg in NREH(SBP; P less than 0.01, DBP; P less than 0.01), 165 +/- 12/94 +/- 8 to 202 +/- 12/126 +/- 9 mmHg in LREH(SBP; P less than 0.001, P less than 0.001) and 118 +/- 8/72 +/- 7 mmHg to 136 +/- 11/88 +/- 8 mmHg in controls (SBP; P less than 0.01, DBP; P less than 0.01). The elevation in NREH and LREH was greater than that in HREH and controls. The elevations of BP both in APA and IHA were remarkably greater than that in controls and as similar as LREH(APA; 174 +/- 21/103 +/- 12 to 204 +/- 18/136 +/- 8 mmHg, IHA; 176 +/- 10/104 +/- 4 to 206 +/- 17/138 +/- 10 mmHg). The elevation in RVH was similar to that in NREH(173 +/- 9/108 +/- 8 to 194 +/- 13/132 +/- 10 mmHg). 2) Plasma P increased from 25.5 +/- 7.5 to 39.5 +/- 13.8 ng/100 ml(P less than 0.001) in HREH, from 28.0 +/- 7.7 to 45.3 +/- 12.7 ng/100 ml(P less than 0.001) in NREH, from 23.8 +/- 8.2 to 47.2 +/- 19.4 ng/100 ml(P less than 0.001) in LREH and 26.6 +/- 11.0 to 43.4 +/- 14.6 ng/100 ml in controls. The increment in HREH or NREH was similar to that in controls(P less than 0.1, respectively), whereas greater than controls in LREH(P less than 0.05).(ABSTRACT TRUNCATED AT 400 WORDS)

Topics: Adrenal Cortex; Adrenal Cortex Hormones; Adult; Aldosterone; Angiotensin II; Angiotensin III; Circadian Rhythm; Corticosterone; Female; Humans; Hydrocortisone; Hydroxyprogesterones; Hyperaldosteronism; Hypertension; Hypertension, Renovascular; Infusions, Intravenous; Male; Middle Aged; Progesterone

Angiotensin-activated neurons were examined using microiontophoretic methods in the paraventricular nucleus (PNV) of the rat. In all cases angiotensin III (AIII) was more potent than angiotensin II (AII). This greater sensitivity to AIII was manifested by lower thresholds, shorter latencies, and higher spike frequencies/amplitudes of applied current. The superior potency of AIII was further exaggerated in the spontaneously hypertensive rat (SHR) compared with normotensive Wistar Kyoto (WKY) rats. Postactivity for both AII and AIII was greatly prolonged in SHR. This appeared specific since no prolongation in acetylcholine postactivity was seen in SHR. These data support the notion that AIII may be the centrally active form of angiotensin and are consistent with an obligatory conversion of AII to AIII prior to activation. The selective enhancement of postactivity observed in SHR following angiotensin application suggests a possible defect in signal termination.

Topics: Angiotensin II; Angiotensin III; Animals; Female; Hypertension; Iontophoresis; Paraventricular Hypothalamic Nucleus; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Species Specificity

The effect of acute intracerebroventricular (i.c.v.) injections of angiotensin II and III (ANG II and ANG III; 0, 1, 10 and 100 pmol in 2 microliters artificial cerebrospinal fluid (CSF) on blood pressure and water consumption was investigated in Okamoto-Aoki spontaneously hypertensive rats (SHR), and Wistar-Kyoto (WKY) and Sprague-Dawley (SD) normotensive controls. Heightened sensitivity to i.c.v. ANG II and ANG III was observed in the SHR compared with the WKY and SD strains (P less than 0.001), for both pressor and drinking responses. In addition, i.c.v. treatment with an aminopeptidase B inhibitor, bestatin (20 nmol in 1 microliter artificial CSF) significantly potentiated the heightened pressor response to i.c.v.-injected ANG II and ANG III (100 pmol) in SHR and to a lesser degree in WKY animals compared with SD controls (P less than 0.001). These results suggest that a dysfunction in central aminopeptidase activity results in an extended life of endogenous angiotensins, and perhaps other peptides that may contribute to the high blood pressure seen in this animal model of human essential hypertension.

Topics: Angiotensin II; Angiotensin III; Animals; Blood Pressure; Cerebral Ventricles; Drinking; Hypertension; Injections, Intraventricular; Leucine; Male; Rats; Rats, Inbred SHR; Rats, Inbred Strains; Rats, Inbred WKY; Thirst

Alert spontaneously hypertensive (SH) rats, prepared with indwelling carotid artery catheters, demonstrated heightened and prolonged blood pressure (BP) responses to intracerebroventricular (i.c.v.) injections of 10 and 100 pmol angiotensin II and III (AII and AIII) as compared with Wistar-Kyoto (WKY) and Sprague-Dawley normotensive animals. Pretreatment with the aminopeptidase B inhibitor bestatin (10 nmol, i.c.v.) potentiated and prolonged the heightened pressor response to AIII (100 pmol, i.c.v.) in SH rats. These results suggest that dysfunction of angiotensin peptidase activity may be contributing to the progressive and sustained elevations in blood pressure noted to occur in the SH rat model of human essential hypertension.

Topics: Angiotensin II; Angiotensin III; Animals; Blood Pressure; Brain; Endopeptidases; Hypertension; Leucine; Male; Rats; Rats, Inbred SHR; Rats, Inbred Strains; Rats, Inbred WKY

In this study, the effects of angiotensin II (A II, Asn-Arg-Val-Tyr-Val-His-Pro-Phe) and angiotensin III (A III, Arg-Val-Tyr-Ile-His-Pro-Phe) on blood pressure (B.P.), pulse rate, several hormones [plasma renin activity (PRA), plasma aldosterone (PA), ACTH, plasma cortisol (PC), urinary catecholamines and urinary aldosterone] and urinary electrolytes were investigated in 9 male patients with essential hypertension [mean age 36.2 +/- 4.1 (S.E.) years]. A II and A III infusions (8 ng/kg/min, 60 min) were started from 0900 h and blood samples were drawn before, at 15, 30, 45, 60 min after the beginning of the infusions, and at 15 min after their cessation. Urinary samples were collected within 2 hrs before and after the infusions, respectively. A II significantly increased B.P.(p less than 0.01) during the infusions, whereas A III did not increase B.P.. PRA significantly decreased after the infusions of A II and A III (p less than 0.05), but the potency of A II was significantly greater than that of A III (p less than 0.01). PA was increased after both infusions, but in response to A III, a peak was observed at 30 min after the infusion and subsequently, the levels decreased gradually. Significant differences between both responses were found at 45 and 60 min (p less than 0.05) after the infusions. ACTH was unchanged during the infusions, but PC was equipotentially suppressed during the infusions, with the suppression of A II being similar to that of A III. In the responses of urinary catecholamines, noradrenaline and dopamine were equipotentially decreased after the infusions (p less than 0.05). The results of the present study clearly indicate that several differences exist between the biological activities of A II and those of A III. Further systematic experimental studies are needed to resolve the details.

Topics: Adrenocorticotropic Hormone; Adult; Aldosterone; Angiotensin II; Angiotensin III; Blood Pressure; Catecholamines; Glomerular Filtration Rate; Hormones; Humans; Hydrocortisone; Hypertension; Male; Renin

We report here on the extraction and characterization of angiotensin I (ANG I) and angiotensin II (ANG II) from the brain of rats. High pressure liquid chromatography (HPLC) with different mobile phases combined with specific radioimmunoassays (RIA) proved to be a powerful tool for peptide characterization in biological samples; (Ile5)-ANG I, (Ile5)-ANG II and (Ile5)-ANG III could clearly be identified in cerebrospinal fluid (CSF), incubated in vivo and in vitro with renin, in total brain extracts, as well as in hypothalamus (HT), medulla oblongata (MO), cerebellum (CER) and cortex (CO). Angiotensin cleaved from CSF angiotensinogen and angiotensin extracted from brain showed retention times identical to those of plasma angiotensin and synthetic standard peptides, indicating that their amino acid sequence is probably identical. ANG I and ANG II were highest in the HT and lowest in the CO. Following bilateral nephrectomy (NX) both ANG I and ANG II persisted at control levels. Young 10 week old spontaneously hypertensive rats (SHRSP) showed significantly lower ANG I and ANG II concentrations in the HT compared with Wistar Kyoto rats (WKY). Intracerebroventricular (i.c.v.) administration of the converting enzyme inhibitor captopril caused a significant increase in ANG 1 in nephrectomized SHRSP but not in WKY. These differences were not found in 40 week old SHRSP. The data show that ANG I and ANG II are synthetized in the brain of rats. The lower concentrations and the enhanced accumulation of ANG I after converting enzyme blockade in nephrectomized young SHRSP indicate an increased turnover of angiotensin in hypertensive rats.

Topics: Angiotensin I; Angiotensin II; Angiotensin III; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Animals; Brain; Captopril; Chromatography, High Pressure Liquid; Female; Hypertension; Male; Nephrectomy; Peptide Fragments; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tissue Distribution

Several polar androgens increased the binding of angiotensin and its stimulation of aldosteronogenesis in bovine adrenal glomerulosa cells. The effect was seen only if the steroids were applied to the cells and then washed away. This phenomenon and the technique for demonstrating it may have implications for studies of receptor modulation and for clinical states in which responsiveness to angiotensin is increased.

Topics: Adrenal Cortex; Aldosterone; Androgens; Angiotensin II; Angiotensin III; Animals; Cattle; Cell Membrane; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Humans; Hypertension; Receptors, Angiotensin; Receptors, Cell Surface; Testosterone

The biological actions of angiotensin III (AIII) in animals have been reported to be stimulation of aldosterone secretion and vasoconstriction. However, the biological actions of AIII in human essential hypertension (EH) have not been evaluated. Twenty ng/Kg/min of AIII was infused intravenously for 30 min into 6 normal subjects and 24 patients with EH. The systolic blood pressure was elevated significantly, from 116 +/- 5 (mean +/- SD)/68 +/- 4 to 137 +/- 9/74 +/- 5 mmHg in normal subjects and from 155 +/- 29/95 +/- 17 to 176 +/- 26/106 +/- 20 mmHg in EH patients. The elevation in systolic BP of low-renin EH patients was significantly larger than that of normal-renin EH patients. Plasma renin activity (PRA) decreased significantly from 1.64 +/- 1.07 to 1.21 +/- 1.05 ng/ml/hr in normal subjects and from 0.88 +/- 0.66 to 0.76 +/- 0.63 ng/ml/hr in EH. Plasma aldosterone concentration (PAC) increased significantly from 57 +/- 34 to 116 +/- 34 pg/ml in normal subjects and from 66 +/- 56 to 91 +/- 24 pg/ml/ in EH. There was no significant difference between the increase of PAC in low-renin EH and in normal-renin EH. Plasma cortisol concentration (PCC) did not change in these subjects. There were no significant relationships between the changes of PRA and PAC or PRA and blood pressure. These results suggest that the pressor action of AIII appeared in relation to the basal PRA in EH. In EH, PRA is suppressed by the direct action of AIII in the kidney and neither by increased PAC nor by increased blood pressure. The small changes in blood pressure caused by AII infusion suggest that a test using an AIII infusion for aldosterone stimulation would be preferable to an angiotensin II infusion.

Topics: Adolescent; Adult; Aldosterone; Angiotensin II; Angiotensin III; Blood Pressure; Female; Humans; Hydrocortisone; Hypertension; Infusions, Parenteral; Kidney; Male; Middle Aged; Renin; Renin-Angiotensin System

Cultured JGC contain renin, angiotensin I, angiotensin I-converting enzyme, angiotensin II, and, by implication, the entire RAS. JGC, as transplants, appear to secrete angiotensin II/III directly into the bloodstream to cause hypertension when the renal mass is reduced. There are two main phases of the hypertensive state, an angiotensin-dependent developmental phase and a non-angiotensin-dependent maintenance phase. This model may be useful in attempts to evaluate pro-hypertensive actions of angiotensin other than those due to direct systemic vasoconstriction. Certain of these actions appear to be intrarenal and include the stimulation of sodium reabsorption, a decrease in renopapillary blood flow, the stimulation of prostaglandin synthesis, and a constraint on the antihypertensive function of the RIC.

Topics: Angiotensin II; Angiotensin III; Animals; Captopril; Cells, Cultured; Hypertension; Juxtaglomerular Apparatus; Nephrectomy; Rats; Saralasin

One hundred milligrams of oral captopril (SQ 14225) caused a significant increase in PRA and a significant decrease in plasma aldosterone (PA) in five normal men and five hypertensive patients. Blood pressure (BP) showed no change in the normal men, but it fell significantly in the patients. An iv infusion of 200 ng/kg.min des-Asp1-,Ileu8-angiotensin II (AIIIA) for 2 h caused a significant decrease in PRA and a slight but significant increase in PA, but caused no change in BP in the normal men. When 100 mg captopril were given orally immediately before the start of the AIIIA infusion, BP showed no change in the normal men, but fell in the patients. However, PRA showed a significant decrease and PA showed a slight but significant increase in both the normal men and the patients, except for one patient with renovascular hypertension who showed a decrease in PA. Thus, this suppression of captopril-induced PRA increase by AIIIA, a derivative of angiotensin II, is not related to BP change, and it suggests that the principal cause of the PRA increase after captopril is a disappearance of endogenous angiotensin II.

Topics: Adult; Aldosterone; Angiotensin I; Angiotensin II; Angiotensin III; Blood Pressure; Captopril; Female; Humans; Hypertension; Isoleucine; Kinetics; Male; Middle Aged; Proline; Renin

Twenty-one patients with essential hypertension received a constant infusion of angiotensin II and des-aspartyl1-angiotensin II for 45 min on 2 consecutive days during normal sodium intake. Des-aspartyl1-angiotensin II increased mean blood pressure from 127.5+/-17.7 to 142.3+/-18.8 mmHg and plasma aldosterone concentration from 12.1+/-7.8 to 18.8+/-11.4 ng/100 ml. Although plasma aldosterone concentration elevation was positively correlated with pre-infusion levels of plasma renin activity (r=0.862, p less than 0.001), mean blood pressure elevation was inversely correlated with the values of renin activity (r=-0.599, p less than 0.01). In contrast, elevatins of both plasma aldosterone concentration and mean blood pressure were inversely correlated with pre-infusion levels of plasma renin activity in angiotensin II infusion. Des-asparty1-angiotensin II and angiotensin II were equally effective in suppressing renin release. These data demonstrte that des-aspartyl1-angiotensin II rather than angiotensin II plays an important role in aldosterone production in essential hypertension.

Topics: Adult; Aldosterone; Angiotensin II; Angiotensin III; Blood Pressure; Humans; Hypertension; Middle Aged; Receptors, Angiotensin; Renin

Topics: Angiotensin II; Angiotensin III; Animals; Dogs; Humans; Hypertension; Rabbits; Renin

The effects of intracerebroventricular administrations of three natural angiotensins, angiotensin I (ANG I 3.8 X 10-11-9.4 X10-10 mol/kg body weight), II (9.6 X 10-12-2.4 X 10-10 mol/kg body weight) and III (2.7 X 10-10 2.5 X 10-9 mol/kg body weight) on systemic blood pressure were investigated in conscious rats. Angiotensin II (ANG II), ANG I and angiotensin III (ANG III), increased blood pressure in a dose-related manner. The order of potency of angiotensins was ANG II greater than ANG I greater than ANG III. The intraventricular administration of a converting enzyme inhibitor (SQ 14225, 6.9 X10-8 mol/kg) abolished the central effect of ANG I, while an angiotensin II analogue ([Sar1-Ala8]ANG II, 1.1 X 10-8 mol/kg) administered intraventricularly inhibited the central pressor effects of these three angiotensins. These results suggest that ANG II is a main mediator of the renin-angiotensin system in the central nervous system.

Topics: Angiotensin I; Angiotensin II; Angiotensin III; Angiotensins; Animals; Blood Pressure; Dose-Response Relationship, Drug; Hypertension; Injections, Intraventricular; Male; Rats

Topics: Adrenal Gland Diseases; Adult; Angiotensin II; Angiotensin III; Humans; Hypertension; Hypertension, Renal; Male